An Oncology Immunotherapy Primer for Medical Writers: Understanding Hype Versus Hope
DOI:
https://doi.org/10.55752/amwa.2025.428Abstract
Immunotherapy use in oncology is expanding rapidly. Immune checkpoint inhibitors, chimeric antigen receptor T-cell therapies, and cancer vaccines are providing deep and durable responses, including for those with previously untreatable cancers. Although these advances are certainly exciting, not all patients will respond to or be candidates for this type of treatment. It is important for medical writers to understand both the benefits and limitations of these therapies in order to accurately communicate clear and balanced language to both patients and the public. This article aims to review currently available immunotherapies, common toxicities, considerations for appropriate immunotherapy candidates, barriers to treatment, important resources, and strategies for medical writers to consider when reporting on and writing about the use of immunotherapy in oncology.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright Notice
Authors of manuscripts accepted for publication retain copyright in their work but are required to grant to AMWA exclusive worldwide first publication rights and further grant a nonexclusive license for other uses of the manuscript for the duration of their copyright as outlined in the Agreement on Authors' Rights and Responsibilities. In the same agreement, authors are required to confirm that the material submitted for publication, both in its paper and electronic versions, including reproductions of other works (eg, photographs, maps, etc.) does not infringe upon any existing copyright.
Any reproduction within two years following the date of publication requires the permission of the Editor-in-Chief of the AMWA Journal.
Contact managingeditor@amwa.org for all requests for reuse.


